Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biocon, Ltd.

http://www.biocon.com/

Latest From Biocon, Ltd.

J&J’s Gorsky Offers Leadership Lessons As He Gets Set To Advise Apple

After 34 years of seeing and shaping Johnson & Johnson’s future, executive chair Alex Gorsky has recently joined Apple’s board of directors. At a recent event, he shared lessons for future leaders while unraveling some of the thinking behind decisions taken as chair and CEO

Commercial Business Strategies

What’s Next At Dr Reddy’s: Biologics CDMO, Cell And Gene Therapy Push

Indian firms are getting their act together in areas like cell and gene therapy, with Dr Reddy’s aiming big and readying a facility alongside an alliance with a Chinese firm for a CAR-T therapy. The company is also doubling down in contract development and manufacturing, with an eye on opportunities in biologics.

Commercial India

Biocon ‘Strongly Denies’ Allegations Of Bribery Amid Reports

India’s Biocon has issued a response after a local English-language daily reported allegations that the company and one of its officials was involved in bribing the Joint Drugs Controller to waive Phase III clinical trial data for its proposed NovoLog (insulin aspart) biosimilar.

Legal Issues Biosimilars

Biocon Refutes Graft Charges After Regulatory Official Booked, Says Due Process Followed

Indian investigating agency probes alleged bribe paid to drugs regulator in a case pertaining to the approval process of Biocon Biologics’ insulin aspart. The company strongly denies the allegations, underscoring that all its product approvals are backed by science and clinical data.

Regulation India
See All

Company Information

  • Industry
  • Biotechnology
  • Distributors
  • Medical Devices
  • Pharmaceuticals
  • Services
  • Pharmaceuticals
    • Generic Drugs
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Other Names / Subsidiaries
    • Biocon Sdn Bhd.
    • Biocon Limited
    • Biocon Biologics India Ltd
    • Bicara Therapeutics
UsernamePublicRestriction

Register